extracellular and intracellular tenofovir df and emtricitabine exposure in mucosal tissue after a...
TRANSCRIPT
Extracellular and Intracellular Tenofovir DF and Emtricitabine Exposurein Mucosal Tissue after a Single Dose of
Fixed-Dose TDF/FTC: Implications for Pre-exposure Prophylaxis
Kristine B Patterson, Heather A Prince, Eric Kraft, Amanda Jones, Sunita Paul, Nicholas J Shaheen, Melissa Spacek, Paris E Heidt, Sunila Reddy, Jim Rooney,
Julie B Dumond, Myron S Cohen, and Angela DM Kashuba
University of North Carolina, Chapel Hill, NC USAGilead Sciences, Foster City, CA USA
Truvada® for preventionTenofovir disoproxil fumarate (TDF) + Emtricitabine (FTC)
Daily oral dosing of TDF +/- FTC being evaluated.
There are no PK data in mucosal tissue after a single oral dose of TDF and FTC.
Clinical trials evaluating EPISODIC ORAL dosing are being planned.
Objectives
Primary– To characterize tenofovir and emtricitabine
(TFV/FTC and TFV-DP/FTC-TP) exposure in multiple biological compartments in both men and women after a single oral dose of Truvada®.
Secondary– To analyze the decay characteristics (t1/2) of
TFV/FTC and TFV-DP/FTC-TP concentrations in multiple biological compartments in both men and women after a single oral dose of Truvada®.
Methods
Single site, open-label trial
Healthy HIV-negative men and women (ages 18-40)
– Comprehensive STD screening– Sexually abstinent– Using contraception
Single observed dose of Truvada®
Pharmacokinetic Sampling
Cervical (CT) and Vaginal Tissue (VT)
Rectal Tissue (RT)
Sampling Time (Days)
1 2 5 7 10 14
Blood Plasma (BP), PBMC, Cerv-Vag Fluid (CVF)
Analyses
Sample Analyses:– LC/MS/MS
– TFV and FTC: LLOQ 0.1 ng/mL– TFV-DP and FTC-TP: LLOQ 2-10 fmol
Data Analyses:– Non-compartmental PK (WinNonlin 6.0) (composite)
– Summary statistics (SAS 9.1.3)• AUC TFV and FTC: ng*days/mL or gm
• AUC TFV-DP and FTC-TP: fmol*days/106 cells or 0.2uL
• Penetration ratios (AUC Ratios); – CVF or tissue AUC 0-14d ÷ BP AUC 0-14d
Subject Demographics
Median (range) Females (n=7) Males (n=8)
Age (yrs) 22(21-25)
26(19-37)
BMI (kg/m2) 24.8(21.2-28.6)
23.5(18.8-28.1)
Race 6 White1 Black
5 White2 Asian
Emtricitabine
Time Post Dose (days)
0 2 4 6 8 10 12 14
FT
C C
once
ntra
tion
(ng/
mL)
0.1
1
10
100
Median Blood Plasma Concentrations Can Be Quantified Up to 14 Days Post-Dose
Tenofovir EmtricitabineTenofovir
Time Post Dose (days)
0 2 4 6 8 10 12 14
TF
V C
once
ntra
tion
(ng/
mL)
0.1
1
10
100
AUC (ng*days/mL)
BP 89
t½(hr)
56 BP 60
AUC (ng*days/mL) t½(hr) 67
Tenofovir
Time Post Dose (days)
0 2 4 6 8 10 12 14
TF
V C
on
cen
tra
tion
(n
g/m
L o
r n
g/g
)
0.1
1
10
100
1000
Emtricitabine
Time Post Dose (days)
0 2 4 6 8 10 12 14F
TC
Co
nce
ntr
atio
n (
ng
/mL
or
ng
/g)
0.1
1
10
100
1000
Tenofovir Emtricitabine
rectal tissuerectal tissue
Median Rectal Tissue Concentrations Are Higher Than Blood Plasma Up to 14 Days Post-Dose
AUC
BP 89
AUCRT:BP
33
t½
42
56
RT 266BP 60
AUC AUCRT:BP
4.3
t½
8767
RT 2981
median
Time Post-Dose (days)
1 2 5 7 10 14FT
C-T
P (f
mol
/10
6 c
ells
or 0
.2uL
)
1
10
100
1000
Tenofovir Diphosphate Emtricitabine Triphosphate
Median Intracellular Rectal Tissue Concentrations Can Be Quantified 2-14 Days Post-Dose
AUC
RT 6,495PBMC 10,813
AUC Ratio t½
4556
RT 199PBMC 10,832
AUC AUC Ratio
NA
t½
6787NA
Time Post Dose (days)
1 2 5 7 10 14
TF
V-D
P (
fmol
/10
6 c
ells
or
0.2u
L)
1
10
100
1000
10000
Time Post Dose (days)
1 2 5 7 10 14
TF
V-D
P (
fmol
/10
6 c
ells
or
0.2u
L)
1
10
100
1000
10000
median
Time Post-Dose (days)
1 2 5 7 10 14
FTC
-TP
(fm
ol/1
06 c
ells
or 0
.2uL
)
1
10
100
1000
10000
Emtricitabine
Time Post Dose (days)
0 2 4 6 8 10 12 14F
TC
Co
nce
ntr
atio
n (
ng
/mL
)0.1
1
10
100
1000
Tenofovir
Time Post Dose (days)
0 2 4 6 8 10 12 14
TF
V C
on
cen
tra
tion
(n
g/m
L)
0.1
1
10
100
1000
Tenofovir Emtricitabine
cervicovaginal fluid
cervicovaginal fluid
Median Cervicovaginal Fluid Concentrations Are Higher Than Blood Plasma Up to 14 Days Post-Dose
AUC
CVF 233BP 89
AUCCVF:BP
2.6
t½
5356
CVF 2520BP 60
AUC AUCCVF:BP
42
t½
4367
Emtricitabine
Time Post Dose (days)
0 2 4 6 8 10 12 14
FT
C C
once
ntra
tion
(ng/
mL
or n
g/g)
0.1
1
10
100
1000
Tenofovir
Time Post Dose (days)
0 2 4 6 8 10 12 14
TF
V C
on
cen
tra
tion
(n
g/m
L o
r n
g/g
)
0.1
1
10
100
1000
Tenofovir Emtricitabine
Vaginal and Cervical Tissue Concentrations Are Similar To, or Higher Than, Blood Plasma
Up to 14 Days Post-Dose
AUCCT 510
AUC Ratio5.8
t½
24AUC AUC Ratio
CT 2496 42t½
57VT 50BP 89
11056
VT 419BP 60
3267
0.6 7
cervical tissue
vaginal tissue
cervical tissue
vaginal tissue
median
Time Post-Dose (days)
1 2 5 7 10 14F
TC
-TP
(fm
ol/1
06 c
ells
or
0.2u
L)
1
10
100
1000
Cervical TissueVaginal Tissue
Time Post Dose (days)
1 2 5 7 10 14
TF
V-D
P (
fmo
l/106 c
ells
or
0.2
uL
)
1
10
100
1000
Cervical TissueVaginal Tissue
Tenofovir Diphosphate Emtricitabine Triphosphate
Median Intracellular Vaginal and Cervical Tissue Concentrations Can Be Detected 1-14 Days Post-Dose
AUCCT 132
AUC Ratio
NA
t½
NA148
AUC AUC RatioCT 167
NA
t½
NANAVT 1171
PBMC 10,813 43VT 1492PBMC 10,832 86
Time Post Dose (days)
1 2 5 7 10 14
TF
V-D
P (
fmol
/106 c
ells
or
0.2u
L)
1
10
100
1000
10000
median
Time Post-Dose (days)
1 2 5 7 10 14
FT
C-T
P (
fmol
/10
6 cel
ls o
r 0.
2uL)
1
10
100
1000
10000
Summary and Implications
• Preferential penetration of TFV/FTC seen in this study supports quantification of other ARVs in all mucosal tissues as part of early development strategies for oral PrEP.
• Differential drug terminal elimination (“Tail”) emphasizes consideration for combination therapy esp. episodic dosing.
TFV TFV-DP FTC FTC-TPBlood, PBMCs 14 d 14 d 14 d 10 d
Rectal Tissue AUC RT:BP
3314 d
-14 d
4.314 d
-2 d
Cervicovaginal Fluid AUC CVF:BP
2.614 d
4214 d
Vaginal TissueAUC VT:BP
0.614 d
-14 d
710 d
-2 d
Cervical TissueAUC CT:BP
5.87 d
-14 d
4210 d
-1 d